Cargando…
Anti-HER-2 DNA vaccine protects Syrian hamsters against squamous cell carcinomas
This paper illustrates the efficacy of DNA vaccination through electroporation in the prevention of oral transplantable carcinoma in Syrian hamsters. At 21 and 7 days before tumour challenge, 19 hamsters were vaccinated with plasmids coding for the extracellular and transmembrane domains of rat HER-...
Autores principales: | , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361512/ https://www.ncbi.nlm.nih.gov/pubmed/16265350 http://dx.doi.org/10.1038/sj.bjc.6602853 |
_version_ | 1782153229433307136 |
---|---|
author | Berta, G N Mognetti, B Spadaro, M Trione, E Amici, A Forni, G Di Carlo, F Cavallo, F |
author_facet | Berta, G N Mognetti, B Spadaro, M Trione, E Amici, A Forni, G Di Carlo, F Cavallo, F |
author_sort | Berta, G N |
collection | PubMed |
description | This paper illustrates the efficacy of DNA vaccination through electroporation in the prevention of oral transplantable carcinoma in Syrian hamsters. At 21 and 7 days before tumour challenge, 19 hamsters were vaccinated with plasmids coding for the extracellular and transmembrane domains of rat HER-2 receptor (EC-TM plasmids), whereas 19 control hamsters were injected intramuscularly with the empty plasmid. Immediately following plasmid injection, hamsters of both groups received two square-wave 25 ms, 375 V cm(−1) electric pulses via two electrodes placed on the skin of the injection area. At day 0, all hamsters were challenged in the submucosa of the right cheek pouch with HER-2-positive HCPC I cells established in vitro from an 7,12-dimethylbenz[a]anthracene-induced oral carcinoma. This challenge gave rise to HER-2-positive buccal neoplastic lesions in 14 controls (73.37%), compared with only seven (36.8%, P<0.0027) vaccinated hamsters. In addition, the vaccinated hamsters displayed both a stronger proliferative and cytotoxic response than the controls and a significant anti-HER-2 antibody response. Most of the hamsters that rejected the challenge displayed the highest antibody titres. These findings suggest that DNA vaccination may have a future in the prevention of HER-2-positive human oral cancer. |
format | Text |
id | pubmed-2361512 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2005 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-23615122009-09-10 Anti-HER-2 DNA vaccine protects Syrian hamsters against squamous cell carcinomas Berta, G N Mognetti, B Spadaro, M Trione, E Amici, A Forni, G Di Carlo, F Cavallo, F Br J Cancer Translational Therapeutics This paper illustrates the efficacy of DNA vaccination through electroporation in the prevention of oral transplantable carcinoma in Syrian hamsters. At 21 and 7 days before tumour challenge, 19 hamsters were vaccinated with plasmids coding for the extracellular and transmembrane domains of rat HER-2 receptor (EC-TM plasmids), whereas 19 control hamsters were injected intramuscularly with the empty plasmid. Immediately following plasmid injection, hamsters of both groups received two square-wave 25 ms, 375 V cm(−1) electric pulses via two electrodes placed on the skin of the injection area. At day 0, all hamsters were challenged in the submucosa of the right cheek pouch with HER-2-positive HCPC I cells established in vitro from an 7,12-dimethylbenz[a]anthracene-induced oral carcinoma. This challenge gave rise to HER-2-positive buccal neoplastic lesions in 14 controls (73.37%), compared with only seven (36.8%, P<0.0027) vaccinated hamsters. In addition, the vaccinated hamsters displayed both a stronger proliferative and cytotoxic response than the controls and a significant anti-HER-2 antibody response. Most of the hamsters that rejected the challenge displayed the highest antibody titres. These findings suggest that DNA vaccination may have a future in the prevention of HER-2-positive human oral cancer. Nature Publishing Group 2005-11-28 2005-11-01 /pmc/articles/PMC2361512/ /pubmed/16265350 http://dx.doi.org/10.1038/sj.bjc.6602853 Text en Copyright © 2005 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Translational Therapeutics Berta, G N Mognetti, B Spadaro, M Trione, E Amici, A Forni, G Di Carlo, F Cavallo, F Anti-HER-2 DNA vaccine protects Syrian hamsters against squamous cell carcinomas |
title | Anti-HER-2 DNA vaccine protects Syrian hamsters against squamous cell carcinomas |
title_full | Anti-HER-2 DNA vaccine protects Syrian hamsters against squamous cell carcinomas |
title_fullStr | Anti-HER-2 DNA vaccine protects Syrian hamsters against squamous cell carcinomas |
title_full_unstemmed | Anti-HER-2 DNA vaccine protects Syrian hamsters against squamous cell carcinomas |
title_short | Anti-HER-2 DNA vaccine protects Syrian hamsters against squamous cell carcinomas |
title_sort | anti-her-2 dna vaccine protects syrian hamsters against squamous cell carcinomas |
topic | Translational Therapeutics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361512/ https://www.ncbi.nlm.nih.gov/pubmed/16265350 http://dx.doi.org/10.1038/sj.bjc.6602853 |
work_keys_str_mv | AT bertagn antiher2dnavaccineprotectssyrianhamstersagainstsquamouscellcarcinomas AT mognettib antiher2dnavaccineprotectssyrianhamstersagainstsquamouscellcarcinomas AT spadarom antiher2dnavaccineprotectssyrianhamstersagainstsquamouscellcarcinomas AT trionee antiher2dnavaccineprotectssyrianhamstersagainstsquamouscellcarcinomas AT amicia antiher2dnavaccineprotectssyrianhamstersagainstsquamouscellcarcinomas AT fornig antiher2dnavaccineprotectssyrianhamstersagainstsquamouscellcarcinomas AT dicarlof antiher2dnavaccineprotectssyrianhamstersagainstsquamouscellcarcinomas AT cavallof antiher2dnavaccineprotectssyrianhamstersagainstsquamouscellcarcinomas |